For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
NZ team heralds new era in cancer treatment; trial starting soon
+News
In print
NEWS
NZ team heralds new era in cancer treatment; trial starting soon
Wednesday 13 December 2017, 09:58 AM

Pioneering research by Swee Tan and Tinte Itinteang of the Gillies McIndoe Research Institute has led to the trial of an innovative cancer treatment
GPs will be among health professionals able to refer patients to be considered for the trial of a cancer therapy not yet tried anywhere in the world. The treatment will see a number of well-established drugs repurposed for cancer. Virginia McMillan reports
I believe I will get to see, in my lifetime, cancer becoming a chronic, manageable condition managed by low-cost, widely accessible medications
I, Agadha Wickremesekera, Capital & Coast DHB neurosurgeon Agadha Wickremesekera is co-leading the Gillies McIndoe Research Institute cancer treatment trial
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.